{"id":{"repo_id":"cambridge","oai_identifier":"oai:www.repository.cam.ac.uk:1810/303261"},"canonical_url":"https://search.dev.ndltd.org/etd/cambridge/oai:www.repository.cam.ac.uk:1810/303261","repository":{"repo_id":"cambridge","name":"Cambridge University","base_url":"https://api.repository.cam.ac.uk/server/oai/request"},"display":{"title":"Exploiting a novel organotypic model of SOX2-driven early squamous lung cancer to identify potential routes to chemoprevention","abstract":"Lung cancer is a devastating disease and is the leading cause of cancer related death globally. Squamous cell lung cancer (SQC) accounts for around 25% of all lung cancer diagnoses. Better strategies for the early detection, prevention and treatment of lung cancer are urgently needed. Using a novel in vitro model of SOX2-driven early SQC I performed a screen using tool compounds and compounds in late phase clinical development for potential efficacy in chemoprevention. I combined this approach with targeted genetic ablation studies to identify/characterise targets that may be key to the progression of SOX2-driven squamous cell carcinomas. In particular I highlight an AKT isoform dependence in SQC that could be exploited in future clinical chemoprevention studies.","abstract_html":"Lung cancer is a devastating disease and is the leading cause of cancer related death globally. Squamous cell lung cancer (SQC) accounts for around 25% of all lung cancer diagnoses. Better strategies for the early detection, prevention and treatment of lung cancer are urgently needed. Using a novel in vitro model of SOX2-driven early SQC I performed a screen using tool compounds and compounds in late phase clinical development for potential efficacy in chemoprevention. I combined this approach with targeted genetic ablation studies to identify/characterise targets that may be key to the progression of SOX2-driven squamous cell carcinomas. In particular I highlight an AKT isoform dependence in SQC that could be exploited in future clinical chemoprevention studies.","abstract_has_math":false,"creators":["Barry, Philip Simon"],"institution":"University of Cambridge","degree_name":"Doctor of Philosophy (PhD)","degree_level":"Doctoral","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":["McCaughan, Frank"],"committee_chairs":[],"committee_members":[],"year":2020,"date_issued":"2020-03-21","date_published":"2020-03-21","updated_at":"2026-07-22T22:24:08Z","subjects":["lung cancer","SOX2","squamous","AKT3","chemoprevention","squamous cell lung cancer"],"languages":["en"],"rights":[],"rights_urls":["https://apollo8-f-pro.lib.cam.ac.uk/bitstreams/37f28e44-d168-44aa-9a53-4a4910e98842/download","https://creativecommons.org/licenses/by-nc-nd/4.0/"],"identifier_entries":[{"key":"dc:creator.authoridentifier","label":"Author Identifier","values":["0000000160316347"],"render_values":[{"text":"0000-0001-6031-6347","href":"https://orcid.org/0000-0001-6031-6347","code":true}]}]},"links":{"outbound_url":"https://doi.org/10.17863/CAM.50341","outbound_label":"DOI","outbound_source":"dc:identifier.doi"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["McCaughan, Frank"]},{"key":"dc:creator","label":"Author","values":["Barry, Philip Simon"]},{"key":"dc:creator.authoridentifier","label":"Author Identifier","values":["0000000160316347"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.issued","label":"Date","values":["2020-03-21"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Cambridge"]},{"key":"dc:relation.isreferencedby.uri","label":"Dc Relation Isreferencedby URI","values":["https://www.repository.cam.ac.uk/handle/1810/303261"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["Doctoral"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["Doctor of Philosophy (PhD)"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["lung cancer","SOX2","squamous","AKT3","chemoprevention","squamous cell lung cancer"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["en"]},{"key":"dc:rights","label":"Dc Rights","values":["https://apollo8-f-pro.lib.cam.ac.uk/bitstreams/37f28e44-d168-44aa-9a53-4a4910e98842/download","https://creativecommons.org/licenses/by-nc-nd/4.0/"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.doi","label":"DOI","values":["10.17863/CAM.50341"]},{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://apollo8-f-pro.lib.cam.ac.uk/bitstreams/44e5cb87-5d0e-4526-9e3c-5fcf9dbd0e2a/download"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Lung cancer is a devastating disease and is the leading cause of cancer related death globally. Squamous cell lung cancer (SQC) accounts for around 25% of all lung cancer diagnoses. Better strategies for the early detection, prevention and treatment of lung cancer are urgently needed. Using a novel in vitro model of SOX2-driven early SQC I performed a screen using tool compounds and compounds in late phase clinical development for potential efficacy in chemoprevention. I combined this approach with targeted genetic ablation studies to identify/characterise targets that may be key to the progression of SOX2-driven squamous cell carcinomas. In particular I highlight an AKT isoform dependence in SQC that could be exploited in future clinical chemoprevention studies."]},{"key":"dc:format.checksum.md5","label":"Dc Format Checksum Md5","values":["91b89334b7e67849a138f9cb8d0e10ae","87eda9de84448d1f82354d60eee3eb5f"]},{"key":"dc:title","label":"Title","values":["Exploiting a novel organotypic model of SOX2-driven early squamous lung cancer to identify potential routes to chemoprevention"]}]}],"canonical_facts":{"dc:contributor.advisor":["McCaughan, Frank"],"dc:creator":["Barry, Philip Simon"],"dc:creator.authoridentifier":["0000000160316347"],"dc:date.issued":["2020-03-21"],"dc:description.abstract":["Lung cancer is a devastating disease and is the leading cause of cancer related death globally. Squamous cell lung cancer (SQC) accounts for around 25% of all lung cancer diagnoses. Better strategies for the early detection, prevention and treatment of lung cancer are urgently needed. Using a novel in vitro model of SOX2-driven early SQC I performed a screen using tool compounds and compounds in late phase clinical development for potential efficacy in chemoprevention. I combined this approach with targeted genetic ablation studies to identify/characterise targets that may be key to the progression of SOX2-driven squamous cell carcinomas. In particular I highlight an AKT isoform dependence in SQC that could be exploited in future clinical chemoprevention studies."],"dc:format.checksum.md5":["91b89334b7e67849a138f9cb8d0e10ae","87eda9de84448d1f82354d60eee3eb5f"],"dc:identifier.doi":["10.17863/CAM.50341"],"dc:identifier.uri":["https://apollo8-f-pro.lib.cam.ac.uk/bitstreams/44e5cb87-5d0e-4526-9e3c-5fcf9dbd0e2a/download"],"dc:language":["en"],"dc:publisher.institution":["University of Cambridge"],"dc:relation.isreferencedby.uri":["https://www.repository.cam.ac.uk/handle/1810/303261"],"dc:rights":["https://apollo8-f-pro.lib.cam.ac.uk/bitstreams/37f28e44-d168-44aa-9a53-4a4910e98842/download","https://creativecommons.org/licenses/by-nc-nd/4.0/"],"dc:subject":["lung cancer","SOX2","squamous","AKT3","chemoprevention","squamous cell lung cancer"],"dc:title":["Exploiting a novel organotypic model of SOX2-driven early squamous lung cancer to identify potential routes to chemoprevention"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["Doctoral"],"dc:type.qualificationname":["Doctor of Philosophy (PhD)"]},"updated_at":"2026-07-22T22:24:08Z"}